Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.4%

163 terminated/withdrawn out of 1936 trials

Success Rate

88.1%

+1.6% vs industry average

Late-Stage Pipeline

11%

209 trials in Phase 3/4

Results Transparency

47%

564 of 1209 completed trials have results

Key Signals

234 recruiting564 with results124 terminated39 withdrawn

Enrollment Performance

Analytics

N/A
1003(60.6%)
Phase 2
275(16.6%)
Phase 1
156(9.4%)
Phase 4
125(7.5%)
Phase 3
84(5.1%)
Early Phase 1
13(0.8%)
1656Total
N/A(1003)
Phase 2(275)
Phase 1(156)
Phase 4(125)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1936)

Showing 20 of 1936 trials
NCT05012124Not ApplicableTerminated

Using Technology to Optimize Collaborative Care Management of Depression in Urban and Rural Cancer Centers, SCOPE

Role: lead

NCT06179303Phase 2Recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Role: lead

NCT07224100Phase 2Recruiting

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Role: lead

NCT05057702Not ApplicableRecruiting

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Role: collaborator

NCT06206525Not ApplicableCompleted

Feasibility Trial Using an Inpatient Insulin Dosing Calculator

Role: lead

NCT03670316Phase 4Completed

Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care

Role: collaborator

NCT04334707Recruiting

Kidney Precision Medicine Project

Role: collaborator

NCT05960578Phase 2Active Not Recruiting

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Role: lead

NCT05195918Phase 1Completed

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Role: collaborator

NCT06736444Not ApplicableRecruiting

Brief Interventions to Reduce Comorbid Alcohol and Cannabis Misuse and Sleep Impairment in Young Adults (Rest-Up RCT)

Role: lead

NCT04382677Not ApplicableCompleted

Families Together: Intervention for Reunified Families

Role: lead

NCT06499740Not ApplicableNot Yet Recruiting

Adapting a Brief Suicide Intervention for Pediatric Primary Care: Enhancing Uptake and Impact

Role: lead

NCT06506279Not ApplicableRecruiting

Motor Recovery Through Plasticity-Inducing Cortical Stimulation

Role: lead

NCT06656338Not ApplicableCompleted

Phase 2 Seattle Dietary Biomarkers Development Center

Role: collaborator

NCT05808127Not ApplicableCompleted

Guiding Aging Long-Term Opioid Therapy Users Into Safer Use Patterns

Role: collaborator

NCT03271372Phase 3Active Not Recruiting

Adjuvant Avelumab in Merkel Cell Cancer

Role: lead

NCT06582966Phase 4Completed

Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya

Role: lead

NCT07087587Not ApplicableRecruiting

Sleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA):

Role: collaborator

NCT07208760Phase 2Withdrawn

L9LS-R21 Interaction

Role: collaborator

NCT07495124Phase 2Not Yet Recruiting

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Role: lead